Quote:In a pooled retrospective analysis of 28 heavily pretreated mTNBC patients from three clinical trials, leronlimab was well tolerated with no therapy-limiting toxicities. Remarkably after a median of >60 months 5/28 (17.9%) of patients remain alive.
They should have mentioned that those 5 patients were the ones to receive both leronlimab and a PD-L1 inhibitor. It would have highlighted the effect of restoring immune competency with leronlimab in combination with a PD-L1 ICI.